Our proprietary platform quantifies MHC-presented peptide targets on patient tumors to stratify patients for immunotherapy, while simultaneously discovering the next generation of therapeutic antigens from every sample.
Over 50 pHLA-targeted immunotherapies are in clinical trials. Each one needs confirmation that the peptide target is presented on the patient's tumor, and at sufficient abundance for the therapy to work.
WES and RNA-seq predict which peptides might bind HLA molecules. But fewer than 5% of predicted neoantigens are actually presented on the tumor surface. Expression does not equal presentation.
Unbiased immunopeptidomics identifies presented peptides, but is biased toward high-abundance targets and provides no absolute quantification of target of interest.
PrecisionMHC runs a targeted, quantitative assay that measures copies-per-cell of specific peptide targets alongside unbiased discovery of novel antigens from a single clinical biopsy. We don't predict. We measure.
Every patient sample generates a quantitative presentation report for targets of choice and an unbiased repertoire of antigens that contributes to a growing discovery database.
Fresh-frozen tumor tissue from patient tumor core biopsy.
Targeted quantification of pMHC targets of interest + unbiased DIA/DDA discovery through proprietary MS platform.
Absolute copies-per-cell for each target peptide, plus a full discovery landscape of presented antigens.
Every sample feeds in the proprietary pHLA database — improving target ranking, assay design, and indication selection over time.
Head-to-head comparison against the current approaches.
| Dimension | Genomic Prediction | Discovery MS (DDA) | PrecisionMHC |
|---|---|---|---|
| What is measured | Predicted binding affinity from DNA/RNA | Unbiased peptide IDs from MS | Quantified copies/cell of specific targets + full discovery landscape |
| Sensitivity | N/A — no direct measurement | Biased to high-abundance targets; misses rare targets | Targeted detection as low as ~1 copy/cell |
| Quantification | Binding affinity and predicted confidence score | Semi-quantitative at best | Absolute copies/cell via isotopologue calibration |
| False positive rate | <Less than 5% of predictions are real | >Potential mis-ID in spectra sequence match | Minimal — SIL standard confirms every ID |
| Therapeutic decision | Suggests candidates only | Cannot inform dosing thresholds | Copies/cell inform therapy modality selection |
| Data asset | Mutation calls; no presentation truth | Peptide IDs per client | Cross-client calibrated pHLA atlas |
Deep technical expertise paired with translational urgency.
We're partnering with pharma and biotech companies developing pHLA-targeted immunotherapies and personalized therapies. Let's talk about your program.
